Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has been a global health concern since 2019. The viral spike protein infects the host by binding to angiotensin-converting enzyme 2 (ACE2) expressed on the cell surface, which is then processed by type II transmembrane serine protease. However, ACE2 does not react to SARS-CoV-2 in inbred wild-type mice, which poses a challenge for preclinical research with animal models, necessitating a human ACE2 (hACE2)-expressing transgenic mouse model. Cytokeratin 18 () promoter-derived hACE2 transgenic mice [B6.Cg-Tg(K18-ACE2)2Prlmn/J] are widely used for research on SARS-CoV-1, MERS-CoV, and SARS-CoV-2. However, SARS-CoV-2 infection is lethal at ≥10 PFU and SARS-CoV-2 target cells are limited to type-1 alveolar pneumocytes in K18-hACE2 mice, making this model incompatible with infections in the human lung. Hence, we developed lung-specific SARS-CoV-2 infection mouse models with surfactant protein B () and secretoglobin family 1a member 1 () promoters. After inoculation of 10 PFU of SARS-CoV-2 to the K18-hACE2, SFTPB-hACE2, and SCGB1A1-hACE2 models, the peak viral titer was detected at 2 days post-infection and then gradually decreased. In K18-hACE2 mice, the body temperature decreased by approximately 10°C, body weight decreased by over 20%, and the survival rate was reduced. However, SFTPB-hACE2 and SCGB1A1-hACE2 mice showed minimal clinical signs after infection. The virus targeted type I pneumocytes in K18-hACE2 mice; type II pneumocytes in SFTPB-hACE2 mice; and club, goblet, and ciliated cells in SCGB1A1-hACE2 mice. A time-dependent increase in severe lung lesions was detected in K18-hACE2 mice, whereas mild lesions developed in SFTPB-hACE2 and SCGB1A1-hACE2 mice. Spleen, small intestine, and brain lesions developed in K18-hACE2 mice but not in SFTPB-hACE2 and SCGB1A1-hACE2 mice. These newly developed SFTPB-hACE2 and SCGB1A1-hACE2 mice should prove useful to expand research on hACE2-mediated respiratory viruses.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706212PMC
http://dx.doi.org/10.3389/fimmu.2022.1055811DOI Listing

Publication Analysis

Top Keywords

k18-hace2 mice
20
sftpb-hace2 scgb1a1-hace2
20
scgb1a1-hace2 mice
20
mice
13
sars-cov-2 infection
12
mouse models
8
sars-cov-2
8
lung-specific sars-cov-2
8
pfu sars-cov-2
8
pneumocytes k18-hace2
8

Similar Publications

The regulation of angiotensin-converting enzyme 2 (ACE2) expression by medications such as ACE inhibitors (ACEis) and angiotensin receptor blockers (ARBs) has raised critical questions regarding their potential benefits and risks during COVID-19. ACE2, a regulator of blood pressure through the renin-angiotensin system (RAS), is the primary receptor for SARS-CoV-2. ACEis and ARBs can modulate ACE2 expression, potentially exacerbating viral load.

View Article and Find Full Text PDF

The continuous evolution of coronaviruses poses persistent and severe threats to both human and animal health. While α- and β-coronaviruses mainly infect mammals, including humans, γ-coronaviruses predominantly infect poultry, causing substantial economic losses. Their rapid mutation rates and wide host tropism underscore the urgent demand for pan-coronavirus therapeutics.

View Article and Find Full Text PDF

Many SARS-CoV-2 patients experience chronic pulmonary symptoms and long-term inflammation despite viral clearance. While these clinical manifestations have been linked to the dysregulation of the adaptive immune response, the underlying immunopathology remains poorly understood due to a lack of suitable animal models. To investigate long-term pulmonary consequences of SARS-CoV-2 infection, we used a genetic cross of 129 mice and C57BL/6 (B6)-K18-hACE2 transgene mice, a model previously shown to survive infection.

View Article and Find Full Text PDF

Coronaviruses encode nonstructural protein 15 (Nsp15), a conserved endoribonuclease (EndoU) known to suppress host antiviral responses. It is imperative to understand the role of Nsp15/EndoU during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in its primary target respiratory epithelial cells. Using a recombinant wild-type SARS-CoV-2 (rWT) and a mutant with catalytically inactive EndoU (rH234A), we show that the EndoU activity is dispensable for viral replication in Vero cells but critically facilitates immune suppression and infection in physiologically relevant human lung cells, including human lung-derived epithelial cell lines, primary bronchial air-liquid interface cultures, and alveolar type 2 organoids derived from induced pluripotent stem cells.

View Article and Find Full Text PDF

It is estimated that 40% of COVID-19 deaths are due to acute respiratory distress syndrome (ARDS), which is often driven by a pronounced cytokine storm. Among key inflammatory mediators, elevated levels of the chemokine CCL2 have been reported in patients with severe COVID-19, promoting excessive immune cell recruitment and inflammation. Therefore, modulating cell migration to the inflammatory site by silencing relevant cytokines may reduce the effects of the cytokine storm.

View Article and Find Full Text PDF